Company intelligence / Profile preview
Inspiration Biopharmaceuticals
Cambridge, Massachusetts, United Statesinspirationbio.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Inspiration Biopharmaceuticals focused on therapies for rare bleeding disorders. Its lead programs, IB1001 for Hemophilia B and OBI-1 for hemophilia A with inhibitors, were both in pivotal trials or regulatory review when the company faced bankruptcy. IB1001 was placed on clinical hold by the FDA, and both assets were subsequently sold off.
- Therapeutic areas
- Hematology
- Modalities
- Recombinant proteinProteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ipsen Group (strategic development/commercialization partnership)
Beyond the preview
Go deeper on Inspiration Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inspiration Biopharmaceuticals.